丙型肝炎药物研发进展

Progress in hepatitis C drug

全球范围内约有1.7亿人感染丙肝病毒,至今仍无法治愈。在过去的30年中,利巴韦林和α干扰素是仅有的有效治疗药物。但两者效果并不明显,而且有大量副作用。因此,研发新的药物对于丙肝的治疗非常的迫切。通过基于分子结构的药物设计与高效筛选技术,以及免疫疗法的研究进展,已有若干药物可有效的治疗丙肝。本文阐述了在若干年内极有可能用于临床治疗,或已在临床试验中有不错进展的小分子抑制剂以及免疫疗法药物。

There are 170 million individuals worldwide are infected with hepatitis C virus（HCV）.Ribavirin and interferon-α have remained to be the only available medicines for treating hepatitis C patients over the past three decades,although they do not show well efficacy and associated with severe side-effects.Therefore developing new molecular entities that can inhibit HCV replication is urgent.By employing a combination of structure-based drug design and high-throughput screening approaches,several useful compounds for treating HCV infections have been successfully introduced.This review will focus on the small molecular inhibitor and immunotherapy that have made progress in clinical trails and potentially can be used within several years.